CCDC152 Inhibitors
Chemicals that serve as CCDC152 inhibitors function by targeting pathways that are thought to involve or influence the CCDC152 protein. Although the biological role of CCDC152 remains relatively uncharacterized, compounds like Wortmannin and LY294002, which are phosphoinositide 3-kinase (PI3K) inhibitors, may serve to regulate it indirectly by affecting PI3K-related pathways that are frequently involved in protein-protein interactions and cell signaling. Similarly, inhibitors targeting the MAPK family members such as SB203580 (p38 MAPK inhibitor), SP600125 (JNK inhibitor), and PD98059 (MEK inhibitor) can affect CCDC152 since the protein is part of these cascades that control a myriad of cellular activities.
In addition, chemicals like Rapamycin and Bortezomib act upon highly conserved cellular pathways associated with mTOR signaling and protein degradation, respectively. CCDC152 is engaged in these processes, these inhibitors will affect its activity. Aurora kinase inhibitors like ZM-447439 and Alisertib also have the to affect CCDC152 since it is implicated in cell division or chromosomal activities. Hedgehog pathway inhibitors like Cyclopamine and Vismodegib may influence CCDC152 since it plays a role in development or cellular differentiation processes regulated by Hedgehog signaling. These inhibitors, by virtue of their action on these significant pathways, serve as tools to indirectly modulate the function of CCDC152.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, obstructs the phosphatidylinositol 3-kinase pathway by acting on the PI3K subunit p110. Should CCDC152 interact directly or indirectly with PI3K signaling elements, Wortmannin can dampen the functionality of CCDC152 by hindering the pathway's efficiency. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 specifically inhibits PI3K, targeting the ATP-binding site of the enzyme. If CCDC152 is associated with signaling processes where PI3K is crucial, LY294002 can downregulate the protein's activity by quenching the downstream signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, an upstream regulator of ERK. If CCDC152's function is influenced by the Ras-Raf-MEK-ERK pathway, PD98059 can block the phosphorylation steps necessary for signaling, thereby inhibiting the role of CCDC152 in such pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK by blocking ATP binding. If CCDC152 is involved in p38 MAPK pathways which are essential in inflammation and cell differentiation, SB203580 can impair the function of CCDC152 by blocking the pathway at the kinase level. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that hampers the c-Jun N-terminal kinase pathway. If CCDC152 is implicated in cellular processes modulated by JNK, such as apoptosis, SP600125 can act as an indirect inhibitor by inhibiting the JNK pathway and thereby CCDC152 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR by forming a complex with FKBP12 that binds to mTORC1. If CCDC152 is part of processes influenced by mTOR, such as autophagy and cell proliferation, Rapamycin can affect CCDC152 by inhibiting the mTOR pathway. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine inhibits the Hedgehog pathway by binding to Smoothened (SMO). If CCDC152 is involved in the Hedgehog signaling, which is crucial for cellular differentiation, Cyclopamine can inhibit its functionality by negating SMO's effect on the pathway. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $80.00 $96.00 | 1 | |
Vismodegib also inhibits the Hedgehog pathway by targeting Smoothened (SMO). Like Cyclopamine, if CCDC152 is functional within this pathway, Vismodegib can inhibit its activity by blocking SMO, thereby preventing downstream signal transduction. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor, and it prevents the degradation of ubiquitin-tagged proteins. If CCDC152's stability or activity is influenced by proteasomal degradation, Bortezomib can affect it indirectly by obstructing the protein degradation machinery. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM-447439 inhibits Aurora kinases, particularly Aurora A and Aurora B. If CCDC152 has a role in cellular events like chromosomal alignment or spindle assembly, functions often regulated by Aurora kinases, ZM-447439 can serve as an indirect inhibitor by incapacitating these kinases and their downstream effects. | ||||||